azomycin has been researched along with Sarcoma in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (31.25) | 18.7374 |
| 1990's | 2 (12.50) | 18.2507 |
| 2000's | 1 (6.25) | 29.6817 |
| 2010's | 7 (43.75) | 24.3611 |
| 2020's | 1 (6.25) | 2.80 |
| Authors | Studies |
|---|---|
| Abdalah, MA; Budzevich, MM; Bui, MM; Dominguez-Viqueira, W; Gillies, RJ; Huang, S; Jardim-Perassi, BV; Johnson, JO; Martinez, GV; Mu, W; Poleszczuk, J; Reed, DR; Tomaszewski, MR | 1 |
| Constantinidou, A; van der Graaf, WTA | 1 |
| Adkins, DR; Butrynski, JE; Chawla, SP; Cranmer, LD; Ganjoo, KN; Hendifar, AE; Kroll, S; Okuno, SH; Reed, DR; Van Tine, BA | 1 |
| Choy, E; Eisinger-Mathason, TS; Hart, CP; Lee, HJ; Lee, YJ; Park, DJ; Simon, MC; Tap, WD; Yoon, C; Yoon, SS | 1 |
| Ali, M; Babur, M; Bloomer, WD; Cawthorne, C; Julyan, PJ; Lunt, SJ; Papadopoulou, MV; Price, PM; Smigova, A; Stratford, IJ; Telfer, BA; Williams, KJ | 1 |
| Adkins, D; Butrynski, JE; Chawla, SP; Cranmer, LD; Ganjoo, KN; Kroll, S; Langmuir, VK; Lorente, G; Okuno, SH; Rushing, D | 1 |
| Busk, M; Bussink, J; Engelholm, SA; Hansen, AE; Jørgensen, JT; Kjær, A; Kristensen, AT; McEvoy, FJ; van der Kogel, AJ | 1 |
| Chu, T; Li, Z; Liu, X; Wang, X | 1 |
| Chapman, JD; Golberg, LE; Groshar, D; Hoskinson, M; Mannan, RH; McEwan, AJ; Mercer, JR; Parliament, MB; Urtasun, RC; Wiebe, LI | 1 |
| Bataini, JP; Bernier, J; Brugère, J; Brunin, F; de Narbonne, J; Jaulerry, C | 1 |
| Munzenrider, JE | 1 |
| Adams, GE; Dische, S; Flockhart, IR; Foster, JL; Gray, AJ | 1 |
| Paciga, JE; Rauth, AM | 1 |
| Hofer, KG; Hofer, MG; Ieracitano, J; McLaughlin, WH | 1 |
| Adams, GE; Bedwell, J; Bown, SG; Bremner, JC; MacRobert, AJ; Pearson, JK; Phillips, D; Sansom, JM; Stratford, IJ | 1 |
1 review(s) available for azomycin and Sarcoma
| Article | Year |
|---|---|
Recent advances in radiotherapy.
Topics: Breast Neoplasms; Bromodeoxyuridine; Carcinoid Tumor; Elementary Particles; Fast Neutrons; Hot Temperature; Humans; Male; Melanoma; Metronidazole; Neoplasms; Nitroimidazoles; Pancreatic Neoplasms; Prostatic Neoplasms; Protons; Radiation Protection; Radiation Tolerance; Radiation-Sensitizing Agents; Radioisotopes; Radiotherapy Dosage; Radiotherapy, High-Energy; Rectal Neoplasms; Salivary Gland Neoplasms; Sarcoma; Soft Tissue Neoplasms | 1977 |
5 trial(s) available for azomycin and Sarcoma
| Article | Year |
|---|---|
Phase II study of the safety and antitumor activity of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Female; Humans; Male; Middle Aged; Nitroimidazoles; Phosphoramide Mustards; Prodrugs; Sarcoma; Survival Rate; Treatment Outcome | 2014 |
Tumor hypoxia is a therapeutic target in soft-tissue sarcoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Hypoxia; Doxorubicin; Humans; Nitroimidazoles; Phosphoramide Mustards; Sarcoma; Tumor Microenvironment | 2014 |
A phase I study of the safety and pharmacokinetics of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma.
Topics: Abscess; Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Cellulitis; Disease-Free Survival; Doxorubicin; Drug Eruptions; Female; Granulocyte Colony-Stimulating Factor; Humans; Lymphopenia; Male; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Neutropenia; Nitroimidazoles; Phosphoramide Mustards; Sarcoma; Stomatitis; Treatment Outcome; Young Adult | 2011 |
[Clinical testing of the radiosensitizer RO-07-0582 (misonidazole). Dose tolerance, toxicity and pharmacokinetic studies, preliminary report (author's transl)].
Topics: Bone Neoplasms; Clinical Trials as Topic; Glioma; Humans; Kinetics; Misonidazole; Neoplasms; Nitroimidazoles; Otorhinolaryngologic Diseases; Sarcoma | 1978 |
Clinical testing of the radiosensitiser Ro-07-0582. I. Dose tolerance, serum and tumour concentrations.
Topics: Adult; Aged; Biopsy; Breast Neoplasms; Carcinoma; Clinical Trials as Topic; Humans; Middle Aged; Nausea; Neoplasm Metastasis; Nervous System Diseases; Neurologic Examination; Nitroimidazoles; Radiation-Sensitizing Agents; Radiography; Sarcoma; Skull; Taste; Vomiting | 1976 |
10 other study(ies) available for azomycin and Sarcoma
| Article | Year |
|---|---|
Deep-learning and MR images to target hypoxic habitats with evofosfamide in preclinical models of sarcoma.
Topics: Animals; Artificial Intelligence; Cell Line, Tumor; Deep Learning; Disease Models, Animal; Doxorubicin; Ecosystem; Female; Humans; Hypoxia; Magnetic Resonance Imaging; Mice; Mice, Inbred C3H; Mice, SCID; Nitroimidazoles; Phosphoramide Mustards; Prodrugs; Sarcoma; Soft Tissue Neoplasms; Xenograft Model Antitumor Assays | 2021 |
The fate of new fosfamides in phase III studies in advanced soft tissue sarcoma.
Topics: Antineoplastic Agents, Alkylating; Clinical Trials, Phase III as Topic; Evidence-Based Medicine; Humans; Neoplasm Staging; Nitroimidazoles; Phosphoramide Mustards; Randomized Controlled Trials as Topic; Research Design; Risk Factors; Sarcoma; Soft Tissue Neoplasms; Survival Analysis; Time Factors; Treatment Outcome | 2017 |
Hypoxia-activated chemotherapeutic TH-302 enhances the effects of VEGF-A inhibition and radiation on sarcomas.
Topics: Activation, Metabolic; Animals; Antineoplastic Agents; Combined Modality Therapy; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Male; Mice; Mice, Inbred BALB C; Nitroimidazoles; Phosphoramide Mustards; Sarcoma; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2015 |
The hypoxia-selective cytotoxin NLCQ-1 (NSC 709257) controls metastatic disease when used as an adjuvant to radiotherapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Hypoxia; Cell Line, Tumor; Chemotherapy, Adjuvant; Combined Modality Therapy; Drug Administration Schedule; Drug Evaluation, Preclinical; Imidazoles; Lung Neoplasms; Mice; Mice, Inbred C3H; Neoplasm Metastasis; Nitroimidazoles; Quinolines; Sarcoma; Tirapazamine; Triazines | 2010 |
(64)Cu-ATSM and (18)FDG PET uptake and (64)Cu-ATSM autoradiography in spontaneous canine tumors: comparison with pimonidazole hypoxia immunohistochemistry.
Topics: Animals; Autoradiography; Carcinoma; Cell Hypoxia; Coordination Complexes; Copper Radioisotopes; Dogs; Fluorodeoxyglucose F18; Immunohistochemistry; Nitroimidazoles; Organometallic Compounds; Positron-Emission Tomography; Radiopharmaceuticals; Sarcoma; Thiosemicarbazones | 2012 |
Synthesis and in vitro and in vivo evaluation of three radioiodinated nitroimidazole analogues as tumor hypoxia markers.
Topics: Animals; Biomarkers, Tumor; Cell Hypoxia; Cell Line, Tumor; Iodine Radioisotopes; Male; Metabolic Clearance Rate; Mice; Nitroimidazoles; Organ Specificity; Oxygen; Radionuclide Imaging; Radiopharmaceuticals; Sarcoma; Tissue Distribution | 2005 |
Imaging tumor hypoxia and tumor perfusion.
Topics: Brain Neoplasms; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cell Hypoxia; Female; Glioblastoma; Head and Neck Neoplasms; Humans; Iodine Radioisotopes; Lung Neoplasms; Male; Nitroimidazoles; Organotechnetium Compounds; Oximes; Sarcoma; Soft Tissue Neoplasms; Technetium Tc 99m Exametazime; Tomography, Emission-Computed, Single-Photon | 1993 |
Effects of dimethyl sulfoxide and hypoxic cell radiosensitizers on the radiation response of the KHT murine tumor in vivo.
Topics: Animals; Cell Survival; Dimethyl Sulfoxide; Male; Metronidazole; Mice; Mice, Inbred C3H; Neoplasms, Experimental; Nitroimidazoles; Oxygen; Radiation-Protective Agents; Radiation-Sensitizing Agents; Sarcoma | 1977 |
Radiosensitization of hypoxic tumor cells by simultaneous administration of hyperthermia and nitroimidazoles.
Topics: Animals; Carcinoma, Ehrlich Tumor; Cell Survival; Deoxyuridine; Female; Hyperthermia, Induced; Hypoxia; Leukemia L1210; Metronidazole; Mice; Mice, Inbred Strains; Neoplasms; Neoplasms, Experimental; Nitroimidazoles; Radiation Tolerance; Radiation-Sensitizing Agents; Sarcoma | 1977 |
Increasing the effect of photodynamic therapy on the RIF-1 murine sarcoma, using the bioreductive drugs RSU1069 and RB6145.
Topics: Animals; Indoles; Mice; Misonidazole; Nitroimidazoles; Organometallic Compounds; Photochemotherapy; Sarcoma; Tumor Cells, Cultured | 1992 |